Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sudarshan S. Naremaddepalli"'
Autor:
DS Samiulla, Jiju Mani, Nagaraj Gowda, Pottayil G. Sasikumar, Nagesh Gowda, Amit A. Dhudashiya, Sudarshan S. Naremaddepalli, Rashmi Nair, Sreenivas Adurthi, Murali Ramachandra, Srinivaskumar Devarapalli, Raghuveer Ramachandra
Publikováno v:
Cancer Research. 79:4148-4148
Activation of anti-tumor immune response by specific inhibition of PD1 pathway using monoclonal antibodies has now become of the mainstay in cancer therapy as evidenced by its widespread use in an expanding list of indications. Although these antibod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84c5182ca37520904868e16ee9e8236e
https://doi.org/10.1158/1538-7445.am2019-4148
https://doi.org/10.1158/1538-7445.am2019-4148
Autor:
Rajesh Eswarappa, Amit A. Dhudashiya, Kavitha Nellore, DS Samiulla, Sudarshan S. Naremaddepalli, Sasikumar Pottayil, Murali Ramachandra, Archana Bhumireddy, Sandeep Patil, Kiran Aithal, Girish Daginakatte, Gundala Chennakrishna, Wesley Roy Balasubramanian, Priyabrata Chand
Publikováno v:
Cancer Research. 78:3852-3852
Introduction: Most of the immunotherapies currently approved in the clinic target immune checkpoint proteins that suppress T-cell responses. There is growing evidence that the innate immune system also plays an important role in the initiation and pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30daaaf99d5f450b2b4ffc6889037e55
https://doi.org/10.1158/1538-7445.am2018-3852
https://doi.org/10.1158/1538-7445.am2018-3852
Autor:
Sandeep Patil, Pottayil G. Sasikumar, DS Samiulla, Amit A. Dhudashiya, Kiran Aithal, Vijaysai Rayavarapu, Chennakrishnareddy Gundala, Wesley Roy Balasubramanian, Archana Bhumireddy, Murali Ramachandra, Sudarshan S. Naremaddepalli, Girish Daginakatte, Anirudha Lakshminarasimhan
Publikováno v:
Molecular Cancer Therapeutics. 17:B007-B007
Antibodies targeting PD-1 and PD-L1 towards stimulation of T cells have revolutionized cancer therapy because of the highly durable response in multiple cancer indications. Although macrophages and other myeloid immune cells offer much promise as eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::202f5a49032a69c53a5a528d7b2ed7f5
https://doi.org/10.1158/1535-7163.targ-17-b007
https://doi.org/10.1158/1535-7163.targ-17-b007
Autor:
Manikyala Rao Yerramsetti, Murali Ramachandra, Nagaraj Gowda, Raghuveer Ramachandra, Sreenivas Adurthi, Jiju Mani, Srinivasa Rao Bandireddy, Samiulla S. Dodheri, Rashmi Nair, Amit Dhudashia, Pottayil G. Sasikumar, Nagesh Gowda, Sudarshan S. Naremaddepalli
Publikováno v:
Molecular Cancer Therapeutics. 17:B006-B006
With the remarkable success of antibodies focusing on PD-1/PD-L1, the immune checkpoint blockade approach has established itself as a cornerstone to cancer therapy. While PD-1/PD-L1 antibodies primarily focus on T cells to achieve antitumor efficacy,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d75f0c3840514d932003e57ae0d8f6e
https://doi.org/10.1158/1535-7163.targ-17-b006
https://doi.org/10.1158/1535-7163.targ-17-b006
Autor:
Nagaraj Gowda, Sudarshan S. Naremaddepalli, Murali Ramachandra, Samiulla Dhodheri, Sreenivas Adurthi, Amit Dhudashia, Raghuveer Ramachandra, Pottayil G. Sasikumar
Publikováno v:
Molecular Cancer Therapeutics. 14:A96-A96
Highly durable clinical responses observed with antibodies to immune checkpoint receptors such as CTLA4 and PD1 have revolutionized the outlook of cancer therapy. However, while these antibodies show impressive clinical activity, they suffer from the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d4f72a970894a18db1001b8a50d2f2a
https://doi.org/10.1158/1535-7163.targ-15-a96
https://doi.org/10.1158/1535-7163.targ-15-a96